By Fineline Cube 
Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its innovative drug Urece (dotinurad) from its Suzhou manufacturing facility in China. The drug was approved by China’s National Medical Products Administration (NMPA) in December 2024.
First-in-Class URAT1 Inhibitor
Dotinurad is the first-in-class highly selective URAT1 inhibitor for the treatment of gout with hyperuricemia in China. It demonstrates not only effective control of serum uric acid levels without increasing renal burden but also the potential to reduce risks of chronic kidney disease and cardiovascular events.
Significance of the Launch
The commercial release of Urece marks a significant advancement in the treatment landscape for gout patients in China. By effectively managing hyperuricemia and addressing associated complications, Urece offers a promising new option for patients and healthcare providers.-Fineline Info & Tech